Mereo Biophama has successfully raised an impressive $70m (£56m) gross through a private placement with new and current US institutional investors. The fund raise was led by Orbimed and brought in Vivo Capital, Surveyor Capital (a Citadel company), Pontifax Venture Capital, Samsara BioCapital, Commodore Capital, and funds managed by Janus Henderson Investors. Existing investors such as Boxer Capital (Tavistock Group) and Aspire Capital Fund also participated.
04 Jun 2020
Private placement raises $70m (£56m)
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Private placement raises $70m (£56m)
- Published:
04 Jun 2020 -
Author:
Lala Gregorek -
Pages:
2
Mereo Biophama has successfully raised an impressive $70m (£56m) gross through a private placement with new and current US institutional investors. The fund raise was led by Orbimed and brought in Vivo Capital, Surveyor Capital (a Citadel company), Pontifax Venture Capital, Samsara BioCapital, Commodore Capital, and funds managed by Janus Henderson Investors. Existing investors such as Boxer Capital (Tavistock Group) and Aspire Capital Fund also participated.